SCHEMBL6999816

SCHEMBL6999816

COC1(OC)CNS(=O)(=O)c2ccccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.36
GRIA2 P42262 2/20 0.33
KMT2A Q03164 3/20 0.33
KDM4E B2RXH2 2/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
CA12 O43570 4/20 0.33
CA1 P00915 4/20 0.33
CA2 P00918 4/20 0.33
CA9 Q16790 4/20 0.33
CA4 P22748 3/20 0.33
CA7 P43166 3/20 0.33
MEN1 O00255 1/20 0.32
NOX1 Q9Y5S8 1/20 0.32
PLCG1 P19174 1/20 0.31
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
BCHE P06276 1/20 0.30
CA6 P23280 1/20 0.30
CA5A P35218 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6989727 0.70 KEAP1 (0.42) KEAP1GRIA2KMT2AKDM4EPOLB
SCHEMBL6988737 0.70 KEAP1 (0.33) KEAP1GRIA2KMT2ACA12CA1
SCHEMBL6998825 0.68 GAA (0.43) KEAP1GRIA2KMT2APOLBCA12
SCHEMBL448460 0.63 KMT2A (0.39) KMT2AKDM4EPOLBMAPTCA12
SCHEMBL20269442 0.63 KEAP1 (0.50) KEAP1GRIA2KMT2AKDM4ECA12
SCHEMBL22202531 0.63 SIGMAR1 (0.37) KMT2AMAPTCA12CA1CA2
Ammonia Solution, Strong SCHEMBL446104 0.62 KMT2A (0.38) KMT2AKDM4EPOLBMAPTCA12
SCHEMBL21713817 0.61 KEAP1 (0.47) KEAP1GRIA2KMT2ACA12CA1
SCHEMBL31536367 0.61 KMT2A (0.36) KMT2AKDM4EPOLBMAPTCA12
SCHEMBL11075928 0.60 ATM (0.43) KMT2AKDM4EPOLBMAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
EP-0686632-B1 BENZOTHIAZINE DERIVATIVE DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-08-06 EP disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
CN-1281854-A Benzothiazine derivative SUNTORY LTD (JP) 2001-01-31 CN disclosed
CN-1058492-C benzothiazine derivatives SUNTORY LTD (JP) 2000-11-15 CN disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
US-5874429-A ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS SUNTORY LIMITED (JP) 1999-02-23 US disclosed
CN-1119859-A benzothiazine derivatives SUNTORY LTD (JP) 1996-04-03 CN disclosed
EP-0686632-A1 BENZOTHIAZINE DERIVATIVE SUNTORY LIMITED (JP) 1995-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 KEAP1 474/4885GRIA2 1108/4885KMT2A 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.